The partnership with Freenome will allow Walgreens to advance clinical studies of blood-based tests for early cancer detection, which could lead to improved healthcare offerings for its customers. This collaboration may attract more customers and increase Walgreens' market share in the healthcare sector, positively impacting its stock price in the short term.